title: Visual outcome and success of amblyopia treatment in unilateral small posterior lens opacities and lenticonus initially treated nonsurgically.
abstract: OBJECTIVE
  We sought to assess the success of amblyopia treatment in patients with small posterior lens opacities as well as the factors associated with a good visual outcome.
  
  
  METHODS
  This was a retrospective study of patients with posterior lens opacities that initially were thought to be too small in size to warrant cataract surgery. The following variables were examined: cataract type, location, diameter, persistent hyaloid vessel, anisometropia, strabismus, and age of detection. Success of treatment of amblyopia was defined as improvement by at least 0.3 logMAR units. Good visual outcome was defined as 20/40 or better. Amblyopia was treated by glasses, patching, and/or atropine. Patients who failed with conservative treatment or had an increase in cataract size underwent surgery.
  
  
  RESULTS
  Forty-eight (91%) of 53 eyes were amblyopic. Thirty amblyopic eyes had pre- and post-treatment Snellen acuities. Twenty (67%) had their visual acuity (VA) improved by 0.3 logMAR units or greater. None of the measured variables were associated with successful amblyopia treatment. Twenty-five (49%) of 51 patients had a final VA of 20/40 or better. The only variable associated with good visual outcome was cataract type: 18 of 25 (72%) posterior subcapsular cataract and 6 of 23 (32%) posterior lenticonus eyes achieved VA of 20/40 or better (P = 0.008). Six patients who went on to have cataract surgery experienced a larger improvement in BCVA (4.50 logMar units +/- 2.52 lines) compared with patients treated without cataract surgery (2.36 logMar units +/- 3.11 lines).
  
  
  CONCLUSIONS
  Amblyopia treatment was successful in most cases. A small group of patients who underwent cataract surgery experienced a greater VA improvement; however, it was not statistically significant. Further studies are needed to determine which patients would benefit from cataract surgery.
authors.affiliation: Wills Eye Hospital, Philadelphia, PA, USA. gmtravi@uol.com.br
authors.forename: Giovanni M
authors.initials: GM
authors.lastname: Travi
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Schnall
authors.forename: Sharon S
authors.initials: SS
authors.lastname: Lehman
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kelly
authors.forename: Denise
authors.initials: D
authors.lastname: Hug
authors.forename: Vânia N
authors.initials: VN
authors.lastname: Hirakata
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Calhoun
mesh_terms: D000550:Amblyopia / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use; D002386:Cataract / Q000150:complications* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005139:Eyeglasses; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007905:Lens Diseases / Q000150:complications* / Q000628:therapy; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D012189:Retrospective Studies; D012683:Sensory Deprivation; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology*
chemical_list: D009184:Mydriatics; D009883:Ophthalmic Solutions; D001285:Atropine